Efficacy in the margins of NHL with ibrutinib

Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL.

Blood·2025

Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025

Treatment of Relapsed/Refractory CLL Patients With PI3Kδ Inhibitor and Anti-CD20 Antibody Rapidly Decreases Tumor Burden but Could Induce Resistance.

American journal of hematology·2025

Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers.

NEJM evidence·2024

Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL.

Blood·2024

Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia.

Blood advances·2023

Neutrophil-dependent interferonopathy contributes to joint damage in hemophilia.

Blood·2026

Recombinant ADAMTS13 in congenital thrombotic thrombocytopenic purpura: final analysis from a randomized phase 3 trial.

Blood·2026

The stress-sensing MARCH5 axis governs blood cancer apoptotic resilience via tractable protein-protein interactions.

Blood·2026

Rare Hematopoietic Stem Cells resilient to infection-induced stress sense yet withstand inflammation.

Blood·2026

How I Treat Pediatric Hematology-Oncology Patients from Families Identifying as Jehovah's Witnesses.

Blood·2026

Technical Considerations in the choice and use of ctDNA for Large B-cell lymphoma (LBCL).

Blood·2026

Immune context governs stage-specific responses to depleting anti-PD-1 antibody in type 1 diabetes.

Cell biomaterials·2026

Corrected Version: IL-12 p40 Monomer is Different from Other IL-12 Family Members to Selectively Inhibit IL-12Rβ1 Internalization and Suppress EAE.

Journal of clinical & experimental immunology·2026

Correction: Editorial: Immunological mechanisms, clinical presentations, and outcomes of neurological toxicities induced by immune checkpoint inhibitors.

Frontiers in immunology·2026

Related Experiment Videos

Efficacy in the margins of NHL with ibrutinib

Related Concept Videos

Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL.

Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).

Treatment of Relapsed/Refractory CLL Patients With PI3Kδ Inhibitor and Anti-CD20 Antibody Rapidly Decreases Tumor Burden but Could Induce Resistance.

Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers.

Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL.

Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia.

Neutrophil-dependent interferonopathy contributes to joint damage in hemophilia.

Recombinant ADAMTS13 in congenital thrombotic thrombocytopenic purpura: final analysis from a randomized phase 3 trial.

The stress-sensing MARCH5 axis governs blood cancer apoptotic resilience via tractable protein-protein interactions.

Rare Hematopoietic Stem Cells resilient to infection-induced stress sense yet withstand inflammation.

How I Treat Pediatric Hematology-Oncology Patients from Families Identifying as Jehovah's Witnesses.

Technical Considerations in the choice and use of ctDNA for Large B-cell lymphoma (LBCL).

Immune context governs stage-specific responses to depleting anti-PD-1 antibody in type 1 diabetes.

Corrected Version: IL-12 p40 Monomer is Different from Other IL-12 Family Members to Selectively Inhibit IL-12Rβ1 Internalization and Suppress EAE.

Correction: Editorial: Immunological mechanisms, clinical presentations, and outcomes of neurological toxicities induced by immune checkpoint inhibitors.

Related Experiment Videos

Efficacy in the margins of NHL with ibrutinib

Related Concept Videos

Related Articles